This phase 3 RCT (TALENTACE) evaluated on-demand TACE plus atezolizumab (1200 mg IV) and bevacizumab (15 mg/kg IV) every 3 weeks versus on-demand TACE alone in 342 patients with untreated, intermediate-to-high tumour burden unresectable HCC (six-and-twelve score ≥6) across 40 centres in China and Japan, with a median follow-up of 26.25 months.
Adding atezolizumab + bevacizumab to on-demand TACE significantly improved TACE-PFS: median 11.30 months vs. 7.03 months (HR 0.71, 95% CI 0.55–0.92; p=0.0089). Overall survival remained immature at the first interim analysis (median ~34.5 vs. ~35.4 months; HR 0.96, 99.62% CI 0.58–1.58), with no significant difference yet observed.
- Overall survival data are immature and no OS benefit has been demonstrated at this interim analysis. - Trial was conducted exclusively in China and Japan (90% Chinese), limiting generalisability to Western populations. - Open-label design introduces potential performance and assessment bias.
For patients with intermediate-to-high tumour burden unresectable HCC, combining on-demand TACE with atezolizumab + bevacizumab meaningfully delays untreatable progression compared to TACE alone. However, an OS benefit has not yet been confirmed—clinicians should weigh the improved TACE-PFS against the added toxicity burden (notably hypertension 14%, thrombocytopenia 14%, and 5 treatment-related deaths) while awaiting mature OS data.
Explore related topics